Xunji Biotechnology

Xunji Biotechnology is a Shanghai-based biopharmaceutical company specializing in the discovery and development of next-generation targeted protein degraders, with a primary focus on molecular glue degraders (MGDs). Utilizing its proprietary X-Glue platform, the company aims to address "undruggable" targets in oncology and immunology by leveraging high-throughput screening and rational design. Xunji's pipeline includes several early-stage programs targeting validated and novel degradation targets to treat hematological malignancies and solid tumors. The company is backed by prominent venture capital firms and is led by a team with extensive experience in protein degradation and drug discovery.